STOCK TITAN

OnKure Therapeutics, Inc. - OKUR STOCK NEWS

Welcome to our dedicated page for OnKure Therapeutics news (Ticker: OKUR), a resource for investors and traders seeking the latest updates and insights on OnKure Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OnKure Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OnKure Therapeutics's position in the market.

Rhea-AI Summary

OnKure Therapeutics (NASDAQ: OKUR), a clinical-stage biopharmaceutical company specializing in precision oncology medicines, has announced its participation in the Stifel 2024 Healthcare Conference. Nicholas Saccomano, Ph.D., President and CEO, will deliver a corporate presentation on November 18, 2024, at 1:50 p.m. ET in New York.

The presentation will be accessible via live webcast through the 'Events' section of OnKure's website, with a replay available for approximately 90 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
conferences
-
Rhea-AI Summary

OnKure Therapeutics (NASDAQ: OKUR) announced the presentation of two abstracts featuring preliminary clinical and preclinical data for OKI-219, their mutant-selective PI3KαH1047R inhibitor, at the 2024 San Antonio Breast Cancer Symposium (SABCS). The presentations will cover results from the PIKture-01 first-in-human study and preclinical data on OKI-219's enhanced activity in breast cancer models. The symposium will be held both virtually and in-person from December 10-13, 2024. OnKure will host a conference call on December 13 to discuss the preliminary data and provide a corporate update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
conferences clinical trial

FAQ

What is the current stock price of OnKure Therapeutics (OKUR)?

The current stock price of OnKure Therapeutics (OKUR) is $17.54 as of November 8, 2024.

What is the market cap of OnKure Therapeutics (OKUR)?

The market cap of OnKure Therapeutics (OKUR) is approximately 234.5M.

OnKure Therapeutics, Inc.

Nasdaq:OKUR

OKUR Rankings

OKUR Stock Data

234.51M
12.65M
1.45%
59.29%
5.2%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOULDER